Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3CYP11B1DPP4FGFR1FGFR2FGFR3FGFR4HRH1JAK1JAK2JAK3KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITNAOPRD1OPRK1OPRM1PPDGFRBPIK3CDSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASMOTYK2polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 4/20 | 0.43 |
| ▸ | ANPEP | P15144 | 6/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 2/20 | 0.35 |
| ▸ | GABRD | O14764 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.35 |
| ▸ | GABRE | P78334 | 2/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.35 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL18486680 | 0.81 | CA2 (0.35) | LAP3ANPEPERAP1ALDH1A1CA2 | |
| Phosphoric Acid SCHEMBL5964228 | 0.81 | CA2 (0.35) | LAP3ANPEPERAP1ALDH1A1CA2 | |
| Phosphoric Acid SCHEMBL156419 | 0.81 | CA2 (0.35) | LAP3ANPEPERAP1ALDH1A1CA2 | |
| Phosphoric Acid SCHEMBL29163267 | 0.81 | LAP3 (0.39) | LAP3ANPEPERAP1ALDH1A1FDPS | |
| SCHEMBL5515951 | 0.80 | — | — | |
| SCHEMBL130823 | 0.80 | — | — | |
| SCHEMBL15015245 | 0.80 | — | — | |
| Urea SCHEMBL4529306 | 0.79 | — | — | |
| Phosphoric Acid SCHEMBL17107837 | 0.79 | LAP3 (0.33) | LAP3CA2 | |
| Phosphoric Acid SCHEMBL14993966 | 0.79 | LAP3 (0.33) | LAP3CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022089486-A1 | SIRNA FOR INHIBITING PCSK9 GENE EXPRESSION AND MODIFIER THEREOF AND USE THEREOF | 江苏柯菲平医药股份有限公司 | 2022-05-05 | — | — | WO | claimed |
| CN-119614575-A | SiRNA for inhibiting XDH gene expression, conjugate thereof and application thereof | 佑嘉(杭州)生物医药科技有限公司 | 2025-03-14 | — | — | CN | disclosed |
| WO-2025031444-A1 | SIRNA FOR INHIBITING DGAT2 GENE EXPRESSION, SIRNA CONJUGATE OR PRODRUG AND PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 北京福元医药股份有限公司 | 2025-02-13 | — | — | WO | disclosed |
| WO-2024169306-A1 | SIRNA FOR INHIBITING EXPRESSION OF PROGRAMMED CELL DEATH 1 LIGAND 1 GENE, CONJUGATE THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 苏州时安生物技术有限公司 | 2024-08-22 | — | — | WO | disclosed |
| WO-2024169908-A1 | SIRNA FOR REGULATING EXPRESSION OF COMPLEMENT C5, AND CONJUGATE, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | 苏州时安生物技术有限公司 | 2024-08-22 | — | — | WO | disclosed |
| WO-2024169907-A1 | SIRNA FOR REGULATING EXPRESSION OF COMPLEMENT C3, CONJUGATE THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 苏州时安生物技术有限公司 | 2024-08-22 | — | — | WO | disclosed |
| CN-118475374-A | Aptamer, conjugate, composition, preparation method and application | 苏州瑞博生物技术股份有限公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-118434450-A | Conjugate, pharmaceutical composition containing conjugate, preparation method and application | 苏州瑞博生物技术股份有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-113614230-B | Nucleic acid, pharmaceutical composition and conjugate, and preparation method and application thereof | 苏州瑞博生物技术股份有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-113227376-B | Nucleic acid, pharmaceutical composition and conjugate, and preparation method and application thereof | 苏州瑞博生物技术股份有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-116497024-A | Nucleic acid and composition, preparation method and application thereof | 北京福元医药股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2023116764-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, AND USE OF SAME, COMPOSITION AND CONJUGATE | 苏州瑞博生物技术股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023088455-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION CONTAINING SAME, SIRNA CONJUGATE, PREPARATION METHOD, AND USE | 苏州瑞博生物技术股份有限公司 | 2023-05-25 | — | — | WO | disclosed |
| WO-2023284763-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE, COMPOSITION AND CONJUGATE CONTAINING DOUBLE-STRANDED OLIGONUCLEOTIDE, AND PREPARATION METHODS AND USES | 苏州瑞博生物技术股份有限公司 | 2023-01-19 | — | — | WO | disclosed |
| WO-2023284559-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, AND PREPARATION METHOD AND USE | 苏州瑞博生物技术股份有限公司 | 2023-01-19 | — | — | WO | disclosed |
| CN-113811613-A | Nucleic acid, pharmaceutical composition and conjugate, preparation method and application | 苏州瑞博生物技术股份有限公司 | 2021-12-17 | — | — | CN | disclosed |
| CN-113330117-A | Nucleic acid, composition containing nucleic acid, conjugate, preparation method and application | 苏州瑞博生物技术股份有限公司 | 2021-08-31 | — | — | CN | disclosed |
| CN-108251420-A | Inhibit siRNA, the composition comprising it and its application of CTGF gene expressions in humans and animals | 苏州瑞博生物技术有限公司 | 2018-07-06 | — | — | CN | disclosed |
| CN-108251421-A | Inhibit siRNA, the composition comprising it and its application of COL1A1 gene expressions in humans and animals | 苏州瑞博生物技术有限公司 | 2018-07-06 | — | — | CN | disclosed |
| CN-108239643-A | Inhibit siRNA, the composition comprising it and its application of TIMP-1 gene expressions in humans and animals | 苏州瑞博生物技术有限公司 | 2018-07-03 | — | — | CN | disclosed |